First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).

Clin Infect Dis · 2018 · PMC6160602 · PMID 29590335

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In addition, we showed a trend for higher success rate among PLWH2 starting with baseline CD4 count ≥500 cells/μL than with CD4 <200 cells/μL, pleading for an early start of cART.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.